Journal
JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
Volume 33, Issue 1, Pages 110-136Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/09205063.2021.1975020
Keywords
Antiviral agents; COVID-19; drug repurposing; pharmaceutical excipients; prophylaxis; SARS-CoV-2
Ask authors/readers for more resources
The limited time and large number of deaths due to COVID-19 present a challenge in finding appropriate therapeutic approaches. Drug repositioning and pharmaceutical excipients show promise as fast and effective treatment options, but further verification of their safety and efficacy is required. Meanwhile, alternative methods such as home remedies and phytotherapies are being explored for prevention and therapy in the absence of specific treatments for COVID-19.
The limited time indorsed to face the COVID-19 emergency and large number of deaths across the globe, poses an unrelenting challenge to find apt therapeutic approaches. However, lead candidate selection to phase III trials of new chemical entity is a time-consuming procedure, and not feasible in pandemic, such as the one we are facing. Drug repositioning, an exploration of existing drug for new therapeutic use, could be an effective alternative as it allows fast-track estimation in phase II-III trials, or even forthright compassionate use. Although, drugs repurposed for COVID-19 pandemic are commercially available, yet the evaluation of their safety and efficacy is tiresome and painstaking. In absence of any specific treatment the easy alternatives such as over the counter products, phytotherapies and home remedies have been largely adopted for prophylaxis and therapy as well. In recent years, it has been demonstrated that several pharmaceutical excipients possess antiviral properties making them prospective candidates against SARS-CoV-2. This review highlights the mechanism of action of various antiviral excipients and their propensity to act against SARs-CoV2. Though, repurposing of pharmaceutical excipients against COVID-19 has the edge over therapeutic agents in terms of safety, cost and fast-track approval trial burdened, this hypothesis needs to be experimentally verified for COVID-19 patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available